The bright side of psychedelics: latest advances and challenges in neuropharmacology

A Mastinu, M Anyanwu, M Carone, G Abate… - International Journal of …, 2023 - mdpi.com
The need to identify effective therapies for the treatment of psychiatric disorders is a
particularly important issue in modern societies. In addition, difficulties in finding new drugs …

[HTML][HTML] IUPHAR–invited review-Ibogaine–A legacy within the current renaissance of psychedelic therapy

DC Mash - Pharmacological Research, 2023 - Elsevier
Ibogaine is a powerful psychoactive substance that not only alters perception, mood and
affect, but also stops addictive behaviors. Ibogaine has a very long history of ethnobotanical …

Psychedelics promote structural and functional neural plasticity

C Ly, AC Greb, LP Cameron, JM Wong, EV Barragan… - Cell reports, 2018 - cell.com
Atrophy of neurons in the prefrontal cortex (PFC) plays a key role in the pathophysiology of
depression and related disorders. The ability to promote both structural and functional …

Serotonin transporter–ibogaine complexes illuminate mechanisms of inhibition and transport

JA Coleman, D Yang, Z Zhao, PC Wen, C Yoshioka… - Nature, 2019 - nature.com
The serotonin transporter (SERT) regulates neurotransmitter homeostasis through the
sodium-and chloride-dependent recycling of serotonin into presynaptic neurons,–. Major …

Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes

TK Brown, K Alper - The American Journal of Drug and Alcohol …, 2018 - Taylor & Francis
Background: Ibogaine is a monoterpene indole alkaloid used in medical and nonmedical
settings for the treatment of opioid use disorder. Its mechanism of action is apparently novel …

[HTML][HTML] Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: clinical observations and treatment outcomes

DC Mash, L Duque, B Page - Frontiers in pharmacology, 2018 - frontiersin.org
Ibogaine may be effective for transitioning opioid and cocaine dependent individuals to
sobriety. American and European self-help groups provided public testimonials that …

Bedside to bench: the outlook for psychedelic research

VP Acero, ES Cribas, KD Browne, O Rivellini… - Frontiers in …, 2023 - frontiersin.org
There has recently been a resurgence of interest in psychedelic compounds based on
studies demonstrating their potential therapeutic applications in treating post-traumatic …

The adverse events of ibogaine in humans: an updated systematic review of the literature (2015–2020)

G Ona, JM Rocha, JC Bouso, JEC Hallak, T Borras… - …, 2022 - Springer
Context Ibogaine is the main alkaloid of the African shrub Tabernanthe iboga. It produces
hallucinogenic and psychostimulant effects, but it is currently known for the anti-addictive …

Safety of ibogaine administration in detoxification of opioid‐dependent individuals: a descriptive open‐label observational study

T Knuijver, A Schellekens, M Belgers, R Donders… - …, 2022 - Wiley Online Library
Background and aims Ibogaine is an indole alkaloid used in rituals of the African Bwiti tribe.
It is also used in non‐medical settings to treat addiction. However, ibogaine has been linked …

A transcriptomic analysis in mice following a single dose of ibogaine identifies new potential therapeutic targets

J Biosca-Brull, G Ona, L Alarcón-Franco… - Translational …, 2024 - nature.com
Ibogaine (IBO) is an atypical psychedelic with a complex mechanism of action. To date, the
mechanisms that may underlie its anti-addictive effects are still not defined. This study aims …